Cupid Share: Company Announces Strong Future Revenue and Net Profit CAGR Guidance

Synopsis: Cupid Limited has provided strong FY29 guidance, targeting revenue CAGR of 48 percent and net profit CAGR of 53 percent, driven by FMCG expansion, exports, capacity growth, and new products.

This Small-Cap Stock, engaged in manufacturing and supplying male and female condoms, lubricants, IVD kits, and FMCG wellness products across domestic and international markets, is in focus after the management announced a net profit CAGR guidance of up to 53 percent.

With a market capitalization of Rs. 15,356.03 crore, the shares of Cupid Limited were currently trading at Rs. 114.20 per equity share, down nearly 5.54 percent from its previous day’s close price of Rs. 120.90.

Management Guidance:

Cupid Limited has outlined a strong strategic growth outlook for the coming years, supported by expanding FMCG distribution, increasing international opportunities, and ongoing capacity expansion plans. The company aims to strengthen its presence across domestic and global markets while focusing on long-term growth and operational efficiency.

Cupid Limited has provided ambitious medium-term financial targets for FY27 to FY29. The company expects revenue to reach Rs. 600 crore in FY27, Rs. 875 crore in FY28, and Rs. 1,150 crore in FY29. Net profit targets are projected at Rs. 180 crore, Rs. 275 crore, and Rs. 390 crore, respectively.

The company has also guided for revenue CAGR growth of up to 48 percent and net profit CAGR growth of up to 53 percent by FY29. Cupid Limited plans to achieve this through the rapid expansion of its FMCG distribution network across India and a higher contribution from its high-margin B2C business. 

The company is also focusing on increasing exports, expanding capacity for male and female condoms, launching new products in lubricants, wellness, and diagnostics, and improving operational efficiencies through better scale and backward integration benefits.

Q4 FY26 Result Walkthrough:

Coming into the quarterly results of Cupid Limited, the company’s consolidated revenue from operations increased by 116.39 percent YOY, from Rs. 61 crore in Q4 FY25 to Rs. 132 crore in Q4 FY26, and grew by 26.92 percent QoQ from Rs. 104 crore in Q3 FY26.

In Q4 FY26, Cupid Limited’s consolidated net profit increased by 200 percent YOY, reaching Rs. 36 crore compared to Rs. 12 crore during the same period last year. As compared to Q3 FY26, the net profit has increased by 9.09 percent, from Rs. 33 crore. The basic earnings per share increased by 200 percent and stood at Rs. 0.27 as against Rs. 0.09 recorded in the same quarter in the previous year, FY2025.

Annual Performance of FY26:

Cupid Limited’s revenue has increased from Rs. 183 crore in FY25 to Rs. 391 crore in FY26, which has grown by 113.66 percent. The net profit has also grown by 163.41 percent from Rs. 41 crore in FY25 to Rs. 108 crore in FY26.

The company successfully surpassed its FY26 guidance of Rs. 335 crore in revenue and Rs. 100 crore in net profit. The strong growth was supported by higher demand, improved operational performance, and expansion across domestic and international markets.

Cupid Limited’s revenue and net profit have grown at a CAGR of 34.98 percent and 50 percent, respectively, over the last three years. In terms of return ratios, the company’s ROCE and ROE stand at 33.5 percent and 27.3 percent, respectively. Cupid Limited has an earnings per share (EPS) of Rs. 0.81, and its debt-to-equity ratio is 0.13x.

Revenue Mix (FY26):

Cupid Limited reported FY26 revenue contribution led by male condoms at Rs. 181.11 crore (51.60 percent), followed by new FMCG products at Rs. 84.26 crore (24.01 percent), female condoms at Rs. 60.72 crore (17.27 percent), and IVD kits & lubricants at Rs. 24.97 crore (7.11 percent).

Company Overview:

Cupid Limited is an Indian healthcare products manufacturer headquartered in Nashik, Maharashtra. Established in 1993, the company specializes in the production of male and female condoms, water-based personal lubricants, and in vitro diagnostic (IVD) kits. 

The company is globally recognized as the first company to achieve World Health Organization and United Nations Population Fund prequalification for both male and female condoms, marking a milestone in quality assurance for reproductive health products.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Cupid Share: Company Announces Strong Future Revenue and Net Profit CAGR Guidance appeared first on Trade Brains.